This contract award to the Massachusetts Institute of Technology (MIT), a world-class private research university, is for the generation of a Broad Agency Announcement (BAA) to address the ongoing growth in continuous manufacturing within cell lines. The $6,038,686 Firm Fixed Price contract is being funded through the President's target increase for focus on advanced manufacturing and will be performed in Cambridge, Massachusetts. The contract has no set-aside designation. This award is likely part of the U.S. Food and Drug Administration's (FDA) agency-wide BAA program that solicits basic and applied research and development proposals to support regulatory science and innovation. The BAA program aims to advance scientific knowledge in specific research areas to assist the FDA in accomplishing its mission to protect and promote the health of the nation.